Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL

NCT00330252 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Rituximab
DRUG: Alemtuzumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]